Alpha-Gal Syndrome, Heart Valves and Cardiac Surgery
Heart surgery is one of the few places in medicine where a person receives large amounts of animal material straight into the bloodstream or sewn into the body. Replacement heart valves are often made from pig or cow tissue, patches that close holes in the heart can be cut from cow pericardium, the blood thinner used during the operation comes from pig or cow tissue, and the sponges and pastes that stop bleeding can be made of gelatin. For people with alpha-gal syndrome (AGS), an allergy to a sugar found in the tissues of non-primate mammals, every one of these is a possible exposure. This page goes deeper into that one setting: what the laboratory studies found, what happened to real patients in published reports, how heart teams described their planning, and how much is still unknown.
The broader background is covered elsewhere on this site: the allergy itself on the Alpha-Gal Syndrome main page, the full list of mammal-derived medicines on Cross-Reactive Medications, and the link between alpha-gal antibodies and coronary plaque on Alpha-Gal Syndrome and Cardiovascular Risk.
Table of Contents
- Why Animal-Derived Medical Products Carry Alpha-Gal
- The Animal-Origin Materials Used in Heart Procedures
- Patients' Serum Binds Valves and Patches in the Laboratory
- Antibodies Against Valve Sugars Track With Valve Wear
- A 2026 Review Found Six Studies and Mixed Outcomes
- Heparin Reactions Range From None to Cardiac Arrest
- Gelatin Hemostats and Plasma Substitutes Have Caused Reactions
- Valve Replacements Have Been Completed With Animal Valves
- How Published Teams Screened and Planned
- What Is Not Known
- Key Research Papers
- Connections
- Featured Videos
Why Animal-Derived Medical Products Carry Alpha-Gal
Galactose-alpha-1,3-galactose, shortened to alpha-gal, is a carbohydrate made by the tissues of mammals other than humans and certain Old World primates. A 2024 narrative review from the University of Virginia describes it as present in a wide range of products derived from mammals, including milk, organs, skeletal muscle and gelatin, as well as products prepared with mammalian cells or ingredients (Zvara 2024). Because the sugar is part of the animal's tissue itself, it does not disappear when that tissue is turned into a medical product.
The same review notes that medications and bioprosthetic implants derived from mammals have caused allergic reactions in people with alpha-gal syndrome, and it describes cardiac surgery in particular as high risk: unfractionated heparin has a bovine (cow) or porcine (pig) origin and is given in large doses for cardiopulmonary bypass, the heart-lung machine, and bioprosthetic valves have similar origins (Zvara 2024).
The sugar survives even the industrial treatments that strip cells out of animal tissue. A 2022 laboratory study concluded that "despite commercial decellularization processes, alpha-gal continues to be present in animal-derived medical products, including bioprosthetic valves" (Kuravi 2022).
Two kinds of antibody appear in this research, and they mean different things. Immunoglobulin E is the allergy antibody; it is what causes hives, a drop in blood pressure and anaphylaxis within minutes to hours. Immunoglobulin G is a different class of antibody; the valve-durability research below is largely about immunoglobulin G and about people who do not necessarily have the allergy at all.
The Animal-Origin Materials Used in Heart Procedures
The published reports read for this page name these categories of animal-derived material in the heart operating room and catheterization laboratory:
- Bioprosthetic heart valves. Replacement valves made from pig valve tissue or from cow pericardium (the sac around the heart). A 2026 laboratory study measured alpha-gal in twelve commercial valve models of both kinds (Colli 2026). Both surgical and transcatheter (through-a-catheter) valves are made this way (Aykut 2025; Lari 2026).
- Bovine pericardial patches. Sheets of cow pericardium used to close holes inside the heart or to repair structures; a 2024 case report describes one used to close an atrial septal defect (Taira 2024), and the 2022 laboratory study tested decellularized cardiac patch materials (Kuravi 2022).
- Heparin. The blood thinner given in high doses for the heart-lung machine and during catheter procedures. Heparin is described as having a bovine or porcine origin (Zvara 2024), and a 2026 case series refers to it as one of the mammalian sources of alpha-gal in cardiac surgery (Lari 2026).
- Gelatin hemostatic agents. Absorbable gelatin matrices, pastes and sponges pressed onto bleeding surfaces. A 2019 case report describes a gelatin matrix product that contains porcine gelatin (Lied 2019), and a 2026 review lists gelatin-based hemostatic agents among the exposures that carry risk for people with alpha-gal syndrome (Sami 2026).
- Gelatin-based plasma substitutes. Intravenous fluids, used to restore blood volume, that are made from bovine gelatin. Case reports describe anaphylaxis to succinylated gelatin and to a gelatin-based colloid plasma substitute in people sensitized to alpha-gal (Uyttebroek 2014; Serrier 2021).
- Blood products. In a 2026 case report, a man collapsed during valve and aortic surgery after receiving heparin, fresh frozen plasma and platelets together (Henderson 2026).
Protamine, the drug used at the end of heart surgery to reverse heparin, is a different case. A 2023 review describes it as "a highly basic protein isolated from salmon sperm" and as the only clinically available agent that reverses unfractionated heparin (Levy 2023). Fish are not mammals, so protamine is not a mammalian product. None of the records read for this page tested protamine for alpha-gal. Protamine does cause its own reactions: the same review describes adverse reactions ranging from widened blood vessels to life-threatening heart and lung dysfunction and shock, with the most severe appearing to be hypersensitivity reactions through immunoglobulin E and/or immunoglobulin G (Levy 2023). A 2026 review on cardiovascular hypersensitivity likewise lists protamine and iodinated contrast among medicines that can set off life-threatening reactions through multiple immune pathways (Sami 2026). Those reactions are a separate problem from alpha-gal.
Patients' Serum Binds Valves and Patches in the Laboratory
The first direct test came from a group at Duke University and the University of North Carolina. They took blood serum from people with alpha-gal syndrome and used immunoblot and tissue-staining methods to see whether the patients' immunoglobulin E would stick to common cardiac materials and valves (Kuravi 2022). The result was clear in the test tube: "AGS serum showed strong reactivity to all of the commercially available, nonhuman products tested, including various decellularized cardiac patch materials and bioprosthetic aortic valves." The same serum did not react to tissue prepared from alpha-gal knockout pigs, animals bred without the gene that makes the sugar. The authors wrote that the finding "may have serious potential implications for sensitized patients undergoing cardiac surgery, including early valve failure and accelerated coronary artery disease" (Kuravi 2022).
A 2026 study then counted how much alpha-gal the valves carry. Twelve commercial bioprosthetic valve models were analysed in the laboratory (Colli 2026):
- Valves made from cow pericardium carried on average 4.18 ± 0.72 × 1011 alpha-gal sites per 10 mg of tissue.
- Valves made from pig valve tissue carried a higher mean value of 8.51 ± 2.17 × 1011 per 10 mg.
- Glutaraldehyde, the chemical used to fix valve tissue, hides some of the sugar at first. But glutaraldehyde-fixed pericardium kept in a blood-like fluid for up to 9 years in real time showed up to 60% re-exposure of the previously masked alpha-gal, which the authors link to a gradual breakdown of the glutaraldehyde cross-links.
- An experimental polyphenol treatment, tested in the laboratory, reduced the detectable alpha-gal by approximately 99%.
The authors concluded that commercially available valves "retain a substantial immunogenic burden" from alpha-gal (Colli 2026). Both of these studies were done on tissue and serum in the laboratory. Neither one followed patients, so neither shows how often a reaction or early valve failure happens in a real person.
Antibodies Against Valve Sugars Track With Valve Wear
Bioprosthetic valves are inherently susceptible to structural valve degeneration, which the 2026 valve study attributes to a combination of mechanical stress, fat infiltration, unstable glutaraldehyde cross-links and progressive calcification (Colli 2026). A 2022 study in Nature Medicine asked whether ordinary immunoglobulin G antibodies against two animal sugars, alpha-gal and a second sugar called N-glycolylneuraminic acid (Neu5Gc), could be part of the answer (Senage 2022).
It is the largest study on the question. The international cohort enrolled 1668 patients with up to 15 years of follow-up after aortic valve replacement (34 ± 43 months on average) and collected 4,998 blood samples (Senage 2022). The findings:
- Early signs of structural valve degeneration appeared in fewer than 5% of bioprosthetic valve recipients within 2 years.
- Levels of immunoglobulin G against both alpha-gal and Neu5Gc rose significantly one month after the bioprosthetic valve was implanted.
- These antibody levels then fell, but immunoglobulin G against alpha-gal fell significantly faster in control patients than in people carrying a bioprosthetic valve.
- Neu5Gc, antibodies against it and complement deposits were found in calcified bioprosthetic valves at much higher levels than in calcified natural aortic valves.
- In mice, antibodies against Neu5Gc could not promote calcium deposits on implanted valve tissue that had been engineered to lack both alpha-gal and Neu5Gc.
The authors concluded that valves made from donor tissue lacking these two sugars "could be less prone to immune-mediated deterioration and have improved durability" (Senage 2022). This study was about valve recipients in general, not about people with alpha-gal syndrome, and it measured immunoglobulin G rather than the allergy antibody. Its relevance here is that it shows the immune system does respond to the sugars on a bioprosthetic valve for years after surgery.
A 2026 Review Found Six Studies and Mixed Outcomes
A 2026 review from Columbia University and Duke University searched three databases (Embase, PubMed and Scopus) for original human studies on alpha-gal and bioprosthetic valve degeneration published between January 2014 and December 2025 (Gosden 2026). Six studies met its criteria, which shows how thin the human evidence still is.
The review reported (Gosden 2026):
- Case reports showed "heterogenous clinical outcomes": rapid structural valve degeneration in some alpha-gal-sensitized patients, and tolerance of the implanted valve around the time of surgery and in the short term in others.
- The only study with longitudinal follow-up found that immunoglobulin G responses against alpha-gal were associated with more structural valve degeneration and calcification.
- Another study found no adverse valve outcomes around the time of surgery, though follow-up was limited to the hospital stay.
The authors concluded that immune recognition of alpha-gal "may contribute" to valve degeneration "based on the limited available evidence", that its broader significance "remains uncertain", and that larger prospective studies are required to establish cause and effect and to guide prevention (Gosden 2026). They add that recognising the mechanism may eventually inform how valves are chosen.
Heparin Reactions Range From None to Cardiac Arrest
The best numbers on heparin come from a University of Virginia review of 8819 cardiac operations from 2007 to 2019, which found 17 patients (0.19%) with a positive alpha-gal test before surgery; 4 of them (24%) had a severe allergic reaction, and in the 8 patients with a recent alpha-gal immunoglobulin E level, 4 (50%) reacted (Hawkins 2021). Those who reacted had a median alpha-gal level of 75 IU/mL against 8 IU/mL in those who did not, while heparin doses did not differ. The study is described in more detail on Cross-Reactive Medications; its authors concluded there is "up to a 50% risk of serious allergic reaction to heparin for cardiopulmonary bypass" in this rare group (Hawkins 2021).
Individual case reports show the whole range of outcomes:
- Cardiac arrest. A 2026 case report describes a 64-year-old man with coronary artery disease, admitted with chest pain, who had two episodes of ventricular fibrillation and was resuscitated both times. After discharge he kept having episodes of palpitations, abdominal pain, nausea, vomiting and diarrhea. An immunologist later diagnosed alpha-gal syndrome and raised the possibility that the ventricular fibrillation was linked to a severe reaction to intravenous heparin, together with or independent of the heart attack he was having. His long-running symptoms resolved completely once beef and pork products were removed from his diet (Khanipour 2026).
- Collapse during valve surgery. A 2026 case report describes a 74-year-old man having valve and ascending aortic replacement whose circulation collapsed after he was given heparin, fresh frozen plasma and platelets. A transfusion reaction, cardiogenic shock and sepsis were ruled out, and he recovered within 6 hours of treatment. Only after the operation was he diagnosed with alpha-gal syndrome; he was then treated with dietary restriction and omalizumab. The authors call the case "a heart team clinical conundrum" (Henderson 2026).
- Heparin given without a reaction. A 2019 report is titled "Successful intravenous heparin administration during coronary revascularization surgery in a patient with alpha-gal anaphylaxis history"; no abstract is indexed for it (Mawhirt 2019). In a 2026 case series of three transcatheter valve replacements, heparin given during the procedure caused no adverse reactions in any patient (Lari 2026), and a 31-year-old man had no reaction to heparin during open heart repair in a 2024 case report (Taira 2024).
- Desensitisation. A 2022 case report from Tennessee describes a heparin desensitisation strategy used before cardiopulmonary bypass in a patient with confirmed alpha-gal allergy who had previously not tolerated heparin, and sets out the management before, during and after surgery (McRae 2022).
The non-mammalian blood thinners that exist are listed on Cross-Reactive Medications. A 2024 case report notes that there are currently no guidelines for heparin administration in alpha-gal patients (Taira 2024).
Gelatin Hemostats and Plasma Substitutes Have Caused Reactions
Gelatin is the other large mammalian exposure in the operating room. Its link to alpha-gal was measured in a 2012 study, which found alpha-gal in bovine gelatin colloids at about 0.44 to 0.52 μg per gram of gelatin, and found that both of 2 patients with anaphylaxis caused by gelatin colloid had a positive gelatin skin test (Mullins 2012). The food side of that study is covered on Complete Mammalian Foods List.
Case reports from surgery:
- Gelatin matrix hemostat. A 2019 case report from Norway describes a 71-year-old man who had anaphylaxis during surgery, with cardiovascular events, linked to a topical gelatin hemostatic agent containing porcine gelatin. Only during the allergy workup afterwards did he report a history of red meat allergy and tick bites; he had high levels of immunoglobulin E against alpha-gal (Lied 2019).
- Hemostatic agents with protein derivatives. A 2020 case report, titled as intraoperative anaphylaxis in response to hemostatic agents with protein derivatives, describes a 44-year-old man with alpha-gal syndrome having surgery for a wrist fracture who had raised concerns beforehand about the products used during surgery. The authors' stated aim was to raise awareness of how widely mammalian products are used in surgical hemostatic agents, and they called for device makers to disclose product components (Holbert 2020).
- Succinylated gelatin plasma substitute. A 2014 case report from Belgium describes a 56-year-old woman with meat allergy who had anaphylaxis to succinylated gelatin, a bovine gelatin-based colloid used to replace blood volume. The authors identify alpha-gal as the antigen responsible (Uyttebroek 2014).
- Recurrent reactions. A 2021 letter from France is titled "Recurrent anaphylaxis to a gelatin-based colloid plasma substitute and to cetuximab following sensitisation to galactose-alpha-1,3-galactose"; no abstract is indexed for it (Serrier 2021).
None of these four reports is described as a heart operation. In two of the cases (Lied 2019; Henderson 2026), alpha-gal syndrome was only recognised after the reaction in the operating room.
Valve Replacements Have Been Completed With Animal Valves
Against the laboratory warnings, most published patient outcomes so far have been uneventful in the short term.
The 155-patient cohort. A prospective study at Duke University measured alpha-gal immunoglobulin E in patients having a bioprosthetic aortic valve put in between January 2022 and January 2023 (Aykut 2025). Of 155 patients, 32.7% (n = 19) of the surgical valve patients and 29.9% (n = 29) of the transcatheter valve patients had detectable immunoglobulin E against alpha-gal. None of them had a serious allergic reaction or died in hospital, and hospital stay and valve function were similar across groups. The authors note that this applies to immediate valve function after surgery; the study did not follow the valves over years (Aykut 2025). Detectable antibody is not the same as diagnosed alpha-gal syndrome, and most of these patients were not known to have the allergy.
The 2026 case series. An anesthesiology group at the University of North Carolina reported three patients with documented alpha-gal syndrome who had transcatheter aortic valve replacement (TAVR) with bovine or porcine valves (Lari 2026). All three were evaluated by allergists before the procedure, and two received no drug pre-treatment. Heparin caused no reactions, recovery showed no immediate or delayed allergic response, and follow-up of 4 to 6 years showed no structural valve deterioration attributable to alpha-gal syndrome. The authors conclude that "perioperative hypersensitivity appears to be rare in this population" (Lari 2026). Three patients is a small number, and the parent page Alpha-Gal Syndrome and Cardiovascular Risk summarises the same series.
Single cases:
- An 84-year-old woman with alpha-gal syndrome since a lone star tick bite in 2012, multiple reactions to beef and an alpha-gal immunoglobulin E above 100 kU/L, had transcatheter aortic valve replacement with a bovine valve. She was not considered a candidate for a mechanical valve. Tryptase, a blood marker of mast-cell release, stayed within the normal range (5.2 μg/L) around the procedure, and no hypersensitivity reaction occurred (Patel 2026).
- A 78-year-old man with alpha-gal syndrome and severe aortic stenosis had transcatheter aortic valve replacement with a porcine-derived valve after allergist-guided preparation, without complications (Sami 2025).
- A 72-year-old man with atrial fibrillation, aortic regurgitation and severe alpha-gal allergy had surgical aortic valve replacement with a 25-mm bovine bioprosthetic valve, plus closure of the left atrial appendage, without immediate or short-term complications (Chen 2024).
- A 31-year-old man with a large atrial septal defect and mitral valve prolapse had mitral and tricuspid valve repair and closure of the defect with a bovine pericardial patch. He had no reaction to the heparin or the patch and was doing well one year later. The authors titled their report "a relative not absolute contraindication" and concluded that bovine pericardium and porcine heparin are an option for septal-defect closure in people with milder forms of alpha-gal allergy when other options are not available (Taira 2024).
- A French team used an aortic homograft, a human donor valve, for a patient with aortic stenosis and documented alpha-gal allergy. The authors describe the homograft as an acceptable alternative to standard biological and mechanical valves that sidesteps both a possible allergic reaction and the need for lifelong oral anticoagulation that a mechanical valve brings (Dang Van 2021).
Successful cases are more likely to be written up than routine ones, and short-term success says nothing about how long these valves will last.
How Published Teams Screened and Planned
No guideline sets out how to care for a person with alpha-gal syndrome during heart surgery. What exists is a handful of published approaches, each from one team:
- Blood testing before surgery. The Virginia heparin study authors write that for patients with a clinical suspicion of alpha-gal syndrome they recommend prescreening with immunoglobulin E levels and premedicating before high doses of intravenous heparin (Hawkins 2021). The Duke cohort authors note that alpha-gal screening is not standard before valve replacement (Aykut 2025). A 2026 review states that systematic screening in tick-endemic regions helps identify at-risk patients before procedures (Sami 2026).
- A ratio, not just a level. A 2025 case report describes an alpha-gal immunoglobulin E to total immunoglobulin E ratio of 5% or less as a proposed threshold at which patients can be rechallenged with animal products, and reports a successful valve replacement in a man whose ratio was slightly higher (Sami 2025). The 2026 review adds that emerging diagnostic tools may help separate harmless antibody from clinically significant disease (Sami 2026). How the test is done is covered on Testing and Diagnosis.
- A team that includes an allergist. Every successful case above involved an allergist or immunologist alongside the surgeons and anesthesiologists (Taira 2024; Sami 2025; Patel 2026; Lari 2026). The 2026 review describes collaboration between cardiology and allergy specialists as the way to tailor prophylaxis to each person's sensitization profile (Sami 2026).
- Drug pre-treatment in some, none in others. One team gave cetirizine, omalizumab and 60 mg of prednisone 6 hours before the procedure, then tapered the prednisone and continued fexofenadine and omalizumab for 6 months (Patel 2026). Another gave antihistamines and steroids (Chen 2024). In the three-patient series, two people received no drug pre-treatment at all (Lari 2026).
- Heparin desensitisation. One team built a step-by-step heparin desensitisation before bypass for a patient who had not tolerated heparin (McRae 2022).
- Choosing the valve. Published choices include bovine and porcine bioprosthetic valves with preparation (Chen 2024; Sami 2025; Patel 2026; Lari 2026) and a human donor homograft (Dang Van 2021). In one case a mechanical valve was ruled out for the patient (Patel 2026). The Virginia narrative review sets out that group's own treatment approach before, during and after surgery (Zvara 2024).
The Anaphylaxis Emergency Plan page covers the signs hospitals treat as an emergency. Decisions about any specific operation, valve or pre-treatment belong with the surgical team and an allergist.
What Is Not Known
- How long animal valves last in people with alpha-gal syndrome. The longest follow-up in diagnosed patients is 4 to 6 years in three people (Lari 2026). The 2026 review found the evidence limited and called for larger prospective studies (Gosden 2026).
- Whether the allergy antibody matters for valve wear. The long-term link to valve degeneration was found for immunoglobulin G against alpha-gal in valve recipients in general (Senage 2022; Gosden 2026). Whether immunoglobulin E, the antibody that defines alpha-gal syndrome, adds anything is not established.
- Who will react to heparin. Higher alpha-gal levels were linked to reactions in one center's data (Hawkins 2021), but several people with documented alpha-gal syndrome received heparin without a reaction (Taira 2024; Lari 2026), and the proposed ratio threshold is based on case experience (Sami 2025).
- How many reactions go unrecognised. In two reports the allergy was diagnosed only after the reaction in surgery (Lied 2019; Henderson 2026), and in another the possible heparin link was raised only after discharge (Khanipour 2026).
- Whether treating valve tissue helps patients. Alpha-gal knockout pig tissue did not react with patients' serum (Kuravi 2022), and a polyphenol treatment removed about 99% of detectable alpha-gal in the laboratory (Colli 2026). Neither has been shown to change outcomes in patients.
- How much of the re-exposed sugar matters. Up to 60% re-exposure of masked alpha-gal after 9 years was seen in a laboratory model, not in implanted valves (Colli 2026).
Key Research Papers
- Kuravi KV, Sorrells LT, Nellis JR, Rahman F, Walters AH, Matheny RG, Choudhary SK, Ayares DL, Commins SP, Bianchi JR, Turek JW. Allergic response to medical products in patients with alpha-gal syndrome. J Thorac Cardiovasc Surg. 2022;164(6):e411-e424. PubMed PMID: 33933257
- Gosden J, Ascione G, Wolf S, Turek JW, George I. Alpha-gal xenoantigens in bioprosthetic valve recipients: clinical implications for bioprosthesis longevity. J Cardiothorac Surg. 2026;21(1):719. PubMed PMID: 42226205
- Lari K, Leghari S, Smeltz AM, Patel D, Teeter EG. Alpha-Gal Syndrome-A Case Series of Successful Transcatheter Mammalian-Derived Aortic Valve Replacements. Semin Cardiothorac Vasc Anesth. 2026;30(3):216-220. PubMed PMID: 42375124
- Colli A, Zilla P, Calafiore AM, Padalino M, Naso F, George I. Quantification of Alpha-Gal Expression in Commercial BioProsthetic Heart Valves and Its Potential Mitigation. Struct Heart. 2026;10(3):100739. PubMed PMID: 41646629
- Senage T, Paul A, Le Tourneau T, Fellah-Hebia I, Vadori M, Bashir S, et al. The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. Nat Med. 2022;28(2):283-294. PubMed PMID: 35177855
- Hawkins RB, Wilson JM, Mehaffey JH, Platts-Mills TAE, Ailawadi G. Safety of Intravenous Heparin for Cardiac Surgery in Patients With Alpha-Gal Syndrome. Ann Thorac Surg. 2021;111(6):1991-1997. PubMed PMID: 33031779
- Aykut B, Lim HK, Ngeve SM, Hoover A, Medina CK, Scherba J, Menken A, Overbey DM, Omer TM, Commins SP, Nellis JR, Turek JW. Perioperative Outcomes After Bioprosthetic Valve Replacement in Patients Sensitized to Alpha-Gal. Ann Thorac Surg Short Rep. 2025;3(1):264-268. PubMed PMID: 40098868
- Zvara J, Smith AL, Mazzeffi MA, Kleiman AM, Tanaka K, Smith AR, Wilson JM, McNeil JS. Alpha-Gal Syndrome and Cardiac Surgery. J Cardiothorac Vasc Anesth. 2024;38(11):2805-2811. PubMed PMID: 39097488
- Sami N, Parikh MA, Mihatov N, Frishman WH, Peterson SJ. The Alpha-Gal Syndrome and Hypersensitivity to Biomaterials: Understanding Xenoimmunity. Cardiol Rev. 2026. Online ahead of print. PubMed PMID: 41703677
- Khanipour R, Bera RK, Suarez I, Soltani Moghadam A, Mattumpuram J. Heparin-Induced Anaphylaxis With Cardiac Arrest in a Patient With Alpha-Gal Syndrome: A Case Report. Cureus. 2026;18(6):e110413. PubMed PMID: 42416968
- Henderson JJ, Saleem D, George E, Still S. Intraoperative Anaphylaxis in the Setting of Undiagnosed Alpha-Gal Syndrome: A Heart Team Clinical Conundrum. JACC Case Rep. 2026;31(1):106033. PubMed PMID: 41504355
- Mawhirt SL, Banta E. Successful intravenous heparin administration during coronary revascularization surgery in a patient with alpha-gal anaphylaxis history. Ann Allergy Asthma Immunol. 2019;123(4):399-401. PubMed PMID: 31150778
- McRae AS, Tidwell WP, Patel S, Lombard FW. Heparin desensitisation prior to cardiopulmonary bypass in a patient with alpha-gal allergy. Anaesth Rep. 2022;10(2):e12203. PubMed PMID: 36561536
- Patel R, Patel A, Biswas R, Hsieh B, Ramasamy D, Patel C. Managing Alpha-Gal Allergy in a Case of Bioprosthetic TAVR. Case Reports Immunol. 2026;2026:8190714. PubMed PMID: 42040183
- Sami N, Ravishankar B, Worku B, Khatib D, McGintee E, Sacchi T, Dogan O, Perk G, Reisman M, Mihatov N. Alpha-Gal Syndrome and Aortic Valve Replacement. JACC Case Rep. 2025;30(32):105478. PubMed PMID: 41106900
- Chen S, Zeigler S. Safe Implantation of a Bovine Bioprosthetic Aortic Valve in a Patient With Galactose-α-1,3-Galactose Allergy. Ann Thorac Surg. 2024;118(4):950-952. PubMed PMID: 38996861
- Taira K, Kanade R, Yammine M, Tannous H, Kumar S. Alpha gal syndrome, a relative not absolute contraindication to the use of bovine pericardium to close an intracardiac septal defect: a case report. J Cardiothorac Surg. 2024;19(1):221. PubMed PMID: 38627833
- Dang Van S, Fouquet O, Jeanneteau A, Leclere JM, Baufreton C. Aortic homograft for aortic valve replacement in patient with Alpha-Gal allergy. Gen Thorac Cardiovasc Surg. 2021;69(11):1499-1501. PubMed PMID: 34279773
- Mullins RJ, James H, Platts-Mills TA, Commins S. Relationship between red meat allergy and sensitization to gelatin and galactose-α-1,3-galactose. J Allergy Clin Immunol. 2012;129(5):1334-1342.e1. PubMed PMID: 22480538
- Lied GA, Lund KB, Storaas T. Intraoperative anaphylaxis to gelatin-based hemostatic agents: a case report. J Asthma Allergy. 2019;12:163-167. PubMed PMID: 31354307
- Holbert SE, Patel D, Rizk T, Dimitri NG, Jones M. Intraoperative Anaphylaxis in Response to Hemostatic Agents With Protein Derivatives. Cureus. 2020;12(8):e9881. PubMed PMID: 32963920
- Uyttebroek A, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Anaphylaxis to succinylated gelatin in a patient with a meat allergy: galactose-α(1, 3)-galactose (α-gal) as antigenic determinant. J Clin Anesth. 2014;26(7):574-6. PubMed PMID: 25439422
- Serrier J, Khoy K, Ollivier Y, Gervais R, Le Moel G, Lafosse M, Johnson A, Le Mauff B, Mariotte D. Recurrent anaphylaxis to a gelatin-based colloid plasma substitute and to cetuximab following sensitisation to galactose-alpha-1,3-galactose. Br J Anaesth. 2021;126(6):e200-e202. PubMed PMID: 33810867
- Levy JH, Ghadimi K, Kizhakkedathu JN, Iba T. What's fishy about protamine? Clinical use, adverse reactions, and potential alternatives. J Thromb Haemost. 2023;21(7):1714-1723. PubMed PMID: 37062523
PubMed Topic Searches
- PubMed: alpha-gal and bioprosthetic heart valves
- PubMed: alpha-gal and heparin anaphylaxis
- PubMed: galactose-alpha-1,3-galactose and cardiac surgery
- PubMed: alpha-gal, gelatin and anaphylaxis in surgery
- PubMed: anti-Gal antibodies and bioprosthetic valve deterioration
- PubMed: alpha-gal and pericardial patches
Connections
- Alpha-Gal Syndrome — the main topic page
- Alpha-Gal Syndrome and Cardiovascular Risk — plaque, coronary disease and the cath lab
- Cross-Reactive Medications — every mammal-derived medicine and the non-mammalian options
- Testing and Diagnosis — how alpha-gal immunoglobulin E is measured
- Anaphylaxis Emergency Plan — the signs hospitals treat as urgent
- Complete Mammalian Foods List — gelatin and other hidden sources
- Aortic Stenosis — the most common reason for valve replacement
- Valvular Heart Disease — the heart valve conditions
- Heparin-Induced Thrombocytopenia — a different, non-allergic heparin reaction
- Anaphylaxis — the severe allergic reaction itself